The new obesity drugs work, but it's a dilemma when people have to stop taking them
Briefly

But on Zepbound the newest GLP-1 agonistdrug to launch Meyers lost 35 pounds and loves feeling free from hunger.
More and more people who started taking the new GLP-1 agonist drugs are now confronting the realities of their limitations; medications like Wegovy and Mounjaro tend to help with sustained weight loss only while people are on them.
For many people, like Meyers, facing that resurfaces familiar anxieties about past failures relying on diet and exercise alone.
One early study showed patients regained two-thirds of the weight they lost on a GLP-1 agonist within two years of stopping the medication.
Read at www.npr.org
[
]
[
|
]